An observational study in Pancreas Cancer, Pancreas Neoplasm and Pancreas Cyst, sponsored by Umeå University. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-05.
Sponsored by Umeå University · Observational
Among 54 studies in Pancreatic Neoplasms with a site in Sweden — 19 open to participants now, 24 under way, 7 of them phase 3. Pancreatic Neoplasms · Sweden.
Among the 54 studies in Pancreatic Neoplasms with a site in Sweden, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2021, is one of 12 observational ones, reaches primary completion later than 23 of the 23 other live ones, and was the 34th registered.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,007 are open to participants now.
Browse Pancreatic Neoplasms studies →19 of the 54 studies in Pancreatic Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
GE Healthcare · Sites in Sweden, United States
Ages 18+
Smartwise Sweden AB · Sites in Sweden
Ages 18+
Roberto Valente · Sites in Sweden
Ages 18–85
Incyte Corporation · Sites in Sweden, United States, Australia and 19 more countries
Ages 18+
AstraZeneca · Sites in Sweden, Denmark, Finland and 4 more countries
Ages 18–99
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 746 Pancreatic Neoplasms studies recruiting now, 479 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 11 · Phase 3 15 · Phase 4 5
First in 2001; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 200 across 740 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 175 across the 41 interventional studies, 496 across the 12 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 54 have an industry lead sponsor. The 10 most frequent:
Umeå University is the lead sponsor of 272 studies on the registry; 60 are open to participants now.
Umeå University has 3 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Pancreatic Neoplasms with a site in Sweden that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04927780Phase 3Erasmus Medical CenterPerioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer | 2027-01 |
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT06099119Hospital Clinico Universitario de SantiagoEfficacy of PERT for PEI in Unresectable Pancreatic Cancer. | 2027-06 |
| NCT07191418Roberto ValenteStudy-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Pancreatic Neoplasms with a site in Sweden, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The project aims at analysing prognostic and predictive factors involved in diagnostics and surgical treatment of cysts and tumors in the pancreas and periampullary region using both clinical data and blood and tissue samples for biomarker development and validation.
From november 2021 an onward, study participants will be prospectively enrolled within the observational study. Before that, study participants are retrospectively enrolled. The study has a broad perspective including studies on clinical outcomes and prognostics based on patient and tumor characteristics.
Patients that have been recommended or already undergone surgery for a cyst or tumor in the pancreas or periampullary region
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall survival
Overall survival
Time frame: 10 years
Complications
Clavien-Dindo, Specific procedure related outcomes
Time frame: 10 years
Radical resection
Rates of R0 vs R1/2 resections
Time frame: 10 years
Started Sep 2021 (actual). Primary completion is estimated for Jan 2035, 160 months after the start.
Of 318 non-industry observational studies under Pancreatic Neoplasms, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 182. This study's planned 160 months is above that.
Counting every sponsor, half of 352 studies reached it within 60 months; a quarter within 34 and three quarters within 182.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.